XCath, a medical robotics company developing endovascular surgical systems, secured $30M in funding co-led by Crescent Enterprises and Dr. Fred Moll. The investment brings total funding to $92M and will support continued development and future commercialization of the Iris robotic system.
Telerobotic Stroke Treatment
XCath develops the Iris system for telerobotic mechanical thrombectomy, a procedure used to remove blood clots during stroke treatment. The platform addresses a global shortage of neurointerventional specialists, enabling remote procedures and expanding access to critical care. The system has already been used in complex neurovascular interventions, including robotic treatment of brain aneurysms.
Global Access and Regional Impact
The technology supports a hub-and-spoke care model, allowing specialists in major hospitals to treat patients remotely in smaller facilities. This approach increases access to advanced stroke care, particularly in regions with limited specialist availability. The investment also reflects growing focus on medical technology development across the MENA region.
Cost Efficiency and Healthcare Innovation
XCath’s system is designed to operate with standard monoplane imaging equipment, reducing infrastructure costs compared to traditional setups. The combination of lower costs and remote capabilities enables broader adoption of advanced neurovascular treatment and supports expansion of accessible, technology-driven healthcare solutions worldwide.